Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus docetaxel versus docetaxel in recurrent/metastatic breast cancer
ChiCTR1800016529Phase 4Recruiting
- Sponsor
- Breast Center of Jiangxi Tumor Hospital
- Start
- Aug 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in breast cancer comparing Apatinib + docetaxel with Docetaxel alone (2 arms). Primary endpoint: Progression-free survival. Started Aug 2018; status: recruiting.
02
Drugs
Rivoceranibdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800016529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016529.